NASDAQ:NURO - Neurometrix Stock Price, Price Target & More

$1.49 +0.04 (+2.76 %)

(As of 04/22/2018 05:00 AM ET)

Previous Close$1.49

Today's Range$1.42 - $1.50

52-Week Range$1.20 - $5.44

Volume139,273 shs

Average Volume174,980 shs

Market Capitalization$10.36 million

P/E Ratio-0.13

Dividend YieldN/A

Beta0.25

About Neurometrix (NASDAQ:NURO)

NeuroMetrix, Inc., a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes. Its marketed products include Quell, a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems; DPNCheck, a test used to evaluate systemic neuropathies, such as diabetic peripheral neuropathy; ADVANCE system, a platform for the performance of traditional nerve conduction studies; and SENSUS, a pain therapy device based on transcutaneous electrical nerve stimulation for relief of chronic intractable pain. The company offers its products to consumers, retail merchandisers, direct response TV promoters, health care professionals, managed care organizations, endocrinologists, podiatrists, physicians, neurologists, and physical medicine and rehabilitation centers, as well as primary care, internal medicine, orthopedic, hand, and neurosurgeons. It operates in the United States, Europe, Asia, the Middle East, Mexico, and internationally. NeuroMetrix, Inc. was founded in 1996 and is headquartered in Waltham, Massachusetts.

Receive NURO News and Ratings via Email

Sign-up to receive the latest news and ratings for NURO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:NURO

CUSIPN/A

Webwww.neurometrix.com

Phone781-890-9989

Debt

Debt-to-Equity RatioN/A

Current Ratio1.99%

Quick Ratio1.69%

Price-To-Earnings

Trailing P/E Ratio-0.13

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$17.09 million

Price / Sales0.62

Cash FlowN/A

Price / CashN/A

Book Value$1.85 per share

Price / Book0.81

Profitability

EPS (Most Recent Fiscal Year)($11.60)

Net Income$-12,850,000.00

Net Margins-75.24%

Return on Equity-233.56%

Return on Assets-136.11%

Miscellaneous

Employees41

Outstanding Shares7,140,000

How to Become a New Pot Stock Millionaire

Neurometrix (NASDAQ:NURO) Frequently Asked Questions

What is Neurometrix's stock symbol?

Neurometrix trades on the NASDAQ under the ticker symbol "NURO."

When did Neurometrix's stock split? How did Neurometrix's stock split work?

Neurometrix shares reverse split before market open on Friday, May 12th 2017. The 1-8 reverse split was announced on Thursday, May 11th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 11th 2017. An investor that had 100 shares of Neurometrix stock prior to the reverse split would have 13 shares after the split.

How were Neurometrix's earnings last quarter?

Neurometrix (NASDAQ:NURO) announced its quarterly earnings results on Thursday, July, 21st. The medical device company reported ($42.96) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($7.44) by $35.52. The medical device company earned $2.65 million during the quarter, compared to analyst estimates of $1.22 million. Neurometrix had a negative net margin of 75.24% and a negative return on equity of 233.56%. View Neurometrix's Earnings History.

What price target have analysts set for NURO?

1 brokerages have issued 1 year price targets for Neurometrix's shares. Their predictions range from $3.00 to $3.00. On average, they expect Neurometrix's share price to reach $3.00 in the next twelve months. View Analyst Ratings for Neurometrix.

Who are some of Neurometrix's key competitors?

Some companies that are related to Neurometrix include Cellectar Biosciences (CLRB), ESSA Pharma (EPIX), Cesca Therapeutics (KOOL), Cormedix (CRMD), Prana Biotechnology (PRAN), Sonoma Pharmaceuticals (SNOA), Fibrocell (FCSC), TrovaGene (TROV), ValiRx (VAL), Cyclacel (CYCC), Cytori Therapeutics (CYTX), Achieve Life Sciences (ACHV), Xenetic Biosciences (XBIO), Ultima (N4P), Biocept (BIOC), Ritter Pharmaceuticals (RTTR), Soligenix (SNGX) and Omega Diagnostics Group (ODX).

Who are Neurometrix's key executives?

Neurometrix's management team includes the folowing people:

Dr. Shai N. Gozani, Founder, Chairman, CEO, Pres & Sec. (Age 53)
Mr. Thomas T. Higgins, Sr. VP, CFO, Treasurer & Principal Accounting Officer (Age 66)
Mr. Francis X. McGillin, Sr. VP & Chief Commercial Officer (Age 57)
Mr. Richard J. Thomas, Pres
Mr. Michael J. MacDonald, Sr. VP & GM of Diagnostics

Has Neurometrix been receiving favorable news coverage?

News headlines about NURO stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group rates the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Neurometrix earned a news sentiment score of 0.17 on Accern's scale. They also gave news coverage about the medical device company an impact score of 46.23 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

How do I buy shares of Neurometrix?

Shares of NURO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Neurometrix's stock price today?

One share of NURO stock can currently be purchased for approximately $1.49.

How big of a company is Neurometrix?

Neurometrix has a market capitalization of $10.36 million and generates $17.09 million in revenue each year. The medical device company earns $-12,850,000.00 in net income (profit) each year or ($11.60) on an earnings per share basis. Neurometrix employs 41 workers across the globe.

How can I contact Neurometrix?

Neurometrix's mailing address is 1000 WINTER STREET, WALTHAM MA, 02451. The medical device company can be reached via phone at 781-890-9989 or via email at [email protected]

MarketBeat Community Rating for Neurometrix (NURO)

Community Ranking:		2.7 out of 5 ( )
Outperform Votes:		119 (Vote Outperform)
Underperform Votes:		104 (Vote Underperform)
Total Votes:		223

MarketBeat's community ratings are surveys of what our community members think about Neurometrix and other stocks. Vote "Outperform" if you believe NURO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NURO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Neurometrix (NASDAQ:NURO) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

1 Wall Street analysts have issued ratings and price targets for Neurometrix in the last 12 months. Their average twelve-month price target is $3.00, suggesting that the stock has a possible upside of 101.34%. The high price target for NURO is $3.00 and the low price target for NURO is $3.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	3.00	3.00	3.00	3.00
Ratings Breakdown:	0 Sell Rating(s) 0 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$3.00	$3.00	$3.00	$3.00
Price Target Upside:	101.34% upside	74.42% upside	74.42% upside	74.42% upside

Neurometrix (NASDAQ:NURO) Consensus Price Target History

Price Target History for Neurometrix (NASDAQ:NURO)

Neurometrix (NASDAQ:NURO) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
10/20/2017	HC Wainwright	Reiterated Rating	Buy	$10.00 -> $3.00	N/A
10/21/2016	Rodman & Renshaw	Reiterated Rating	Buy	$36.00	N/A

(Data available from 4/22/2016 forward)

Neurometrix (NASDAQ:NURO) Earnings History and Estimates Chart

Earnings by Quarter for Neurometrix (NASDAQ:NURO)

Neurometrix (NASDAQ NURO) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
10/20/2017	Q3 2017	($1.60)	($3.11)		$3.55 million	View	N/A
7/20/2017	Q2 2017	($2.83)	($2.49)	$4.40 million	$4.31 million	View	N/A
4/20/2017	Q1 2017	($3.92)	($7.28)	$4.17 million	$4.31 million	View	N/A
1/26/2017	Q416	($6.00)	($4.16)	$3.48 million	$3.70 million	View	Listen
10/20/2016	Q316	($6.56)	($6.08)	$3.01 million	$3.39 million	View	Listen
7/21/2016	Q216	($7.44)	($42.96)	$1.22 million	$2.65 million	View	Listen
4/21/2016	Q116	($7.60)	($8.00)	$2.65 million	$2.28 million	View	Listen
2/12/2016	Q4 2015		($25.52)		$2.74 million	View	N/A
10/22/2015	Q315	($0.64)	($2.08)	$6.47 million	$2.10 million	View	Listen
7/22/2015	Q215		($3.84)	$9.80 million	$1.22 million	View	Listen
4/21/2015	Q1 2015		($12.48)		$1.28 million	View	N/A
2/12/2015	Q414		($2.88)	$4.62 million	$1.41 million	View	N/A
10/28/2014	Q3 2014		($8.32)		$1.43 million	View	N/A
7/24/2014	Q413		($6.80)	$1.16 million	$1.34 million	View	N/A
4/24/2014	Q1 2014		($9.60)		$1.33 million	View	N/A
2/13/2014			($6.96)		$1.40 million	View	Listen
10/23/2013	Q313		($2.08)	$1.77 million	$1.31 million	View	Listen
7/25/2013	Q2 2013		($7.36)	$2.20 million	$1.20 million	View	N/A
4/25/2013	Q1 2013		($33.92)		$1.40 million	View	N/A
2/19/2013	Q4 2012	($40.31)	($170.85)			View	N/A
10/25/2012	Q3 2012	($40.31)	($40.31)			View	N/A
7/26/2012	Q2 2012	($40.31)	($42.23)			View	N/A
4/24/2012	Q1 2012	($101.74)	($63.35)			View	N/A
2/15/2012	Q4 2011	($143.97)	($120.94)			View	N/A
10/27/2011	Q3 2011	($161.25)	($120.94)			View	N/A
7/28/2011	Q2 2011	($149.70)	($126.67)			View	N/A
4/28/2011	Q1 2011		($138.18)			View	N/A
2/3/2011		($1.36)	($1.44)			View	N/A
11/9/2010	Q3 2010	($195.76)	($172.73)			View	N/A
8/10/2010	Q2 2010	($230.31)	($230.31)			View	N/A
5/11/2010	Q1 2010	($195.76)	($230.31)			View	N/A
2/10/2010	Q4 2009	($92.12)	($92.12)			View	N/A
11/5/2009	Q3 2009	($241.82)	($132.43)			View	N/A
8/5/2009	Q2 2009	($149.70)	($148.55)			View	N/A
5/6/2009	Q1 2009	($126.67)	($100.18)			View	N/A
2/10/2009	Q4 2008	($218.79)	($84.06)			View	N/A
11/4/2008	Q3 2008	($264.85)	($238.37)			View	N/A
8/5/2008	Q2 2008	($299.40)	($297.10)			View	N/A
5/6/2008	Q1 2008	($241.82)	($365.04)			View	N/A
2/12/2008	Q4 2007	($276.37)	($194.61)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Neurometrix (NASDAQ:NURO) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Neurometrix (NASDAQ NURO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.50%
Institutional Ownership Percentage: 5.69%

Insider Trading History for Neurometrix (NASDAQ:NURO)

Institutional Ownership by Quarter for Neurometrix (NASDAQ:NURO)

Neurometrix (NASDAQ NURO) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/1/2018	Thomas T Higgins	Insider	Buy	1,000	$1.33	$1,330.00	77,196
2/23/2018	Shai Gozani	CEO	Buy	1,500	$1.54	$2,310.00	76,196
2/20/2018	Shai Gozani	CEO	Buy	1,000	$1.36	$1,360.00	73,696
2/20/2018	Thomas T Higgins	Insider	Buy	1,500	$1.36	$2,040.00
2/12/2018	Francis X Mcgillin	SVP	Buy	3,849	$1.30	$5,003.70	8,584
2/12/2018	Thomas T Higgins	Insider	Buy	1,500	$1.34	$2,010.00	29,963
2/9/2018	Shai Gozani	CEO	Buy	5,000	$1.28	$6,400.00	71,196
2/6/2018	Thomas T Higgins	CFO	Buy	1,000	$1.45	$1,450.00	28,463
2/5/2018	Shai Gozani	CEO	Buy	5,000	$1.48	$7,400.00	66,196
2/1/2018	Thomas T Higgins	Insider	Buy	2,500	$1.55	$3,875.00	27,463
1/31/2018	Shai Gozani	CEO	Buy	2,000	$1.69	$3,380.00	59,196
1/29/2018	Shai Gozani	CEO	Buy	1,000	$1.75	$1,750.00	57,196
12/13/2017	Shai Gozani	CEO	Buy	3,000	$1.78	$5,340.00	56,196
12/11/2017	Shai Gozani	CEO	Buy	2,000	$1.70	$3,400.00	51,196
12/7/2017	Shai Gozani	CEO	Buy	6,333	$1.50	$9,499.50	46,196
12/7/2017	Thomas T Higgins	CFO	Buy	2,000	$1.51	$3,020.00	22,963
12/1/2017	Shai Gozani	CEO	Buy	3,000	$1.70	$5,100.00
11/16/2017	Shai Gozani	CEO	Buy	2,000	$1.94	$3,880.00	36,863
10/25/2017	Shai Gozani	CEO	Buy	5,000	$1.67	$8,350.00	34,863
10/25/2017	Thomas T Higgins	Insider	Buy	2,500	$1.70	$4,250.00	20,963
10/23/2017	Thomas T Higgins	Insider	Buy	2,500	$1.77	$4,425.00	18,463
6/21/2017	Thomas T Higgins	Insider	Buy	1,000	$2.83	$2,830.00	15,963
6/16/2017	Shai Gozani	CEO	Buy	3,500	$2.90	$10,150.00	27,363
6/15/2017	Thomas T Higgins	Insider	Buy	3,500	$2.98	$10,430.00	14,963
6/14/2017	Shai Gozani	CEO	Buy	5,000	$2.97	$14,850.00	23,863
6/14/2017	Thomas T Higgins	Insider	Buy	2,300	$2.97	$6,831.00	11,463
11/1/2016	Shai Gozani	CEO	Buy	3,000	$1.31	$3,930.00	150,909
10/28/2016	Thomas T Higgins	Insider	Buy	3,000	$1.32	$3,960.00	73,309
10/27/2016	Shai Gozani	CEO	Buy	6,000	$1.32	$7,920.00	147,909
8/31/2016	Thomas T Higgins	CFO	Buy	1,400	$1.41	$1,974.00	70,309
8/18/2016	Shai Gozani	CEO	Buy	5,000	$1.49	$7,450.00	141,909
8/12/2016	Thomas T Higgins	Insider	Buy	2,000	$1.45	$2,900.00	68,909
6/1/2016	Shai Gozani	CEO	Buy	2,500	$1.71	$4,275.00	139,409
5/23/2016	Francis X Mcgillin	VP	Buy	1,000	$1.65	$1,650.00	37,886
5/19/2016	Shai Gozani	CEO	Buy	12,000	$1.55	$18,600.00	132,409
5/19/2016	Thomas T Higgins	CFO	Buy	3,200	$1.54	$4,928.00	64,909
8/28/2015	Thomas T Higgins	CFO	Buy	4,500	$0.92	$4,140.00	85,494
8/20/2015	Thomas T Higgins	CFO	Buy	5,500	$0.91	$5,005.00	80,994
8/11/2015	Shai Gozani	CEO	Buy	16,300	$0.91	$14,833.00
11/9/2012	Shai Gozani	CEO	Buy	26,800	$0.55	$14,740.00
8/27/2012	Krishnamurthy Balachandran	COO	Buy	5,000	$0.67	$3,350.00
8/21/2012	Thomas T Higgins	CFO	Buy	5,000	$0.64	$3,200.00
8/13/2012	Krishnamurthy Balachandran	COO	Buy	5,000	$0.70	$3,500.00
8/8/2012	Thomas T Higgins	CFO	Buy	5,000	$0.70	$3,500.00

(Data available from 1/1/2013 forward)

Neurometrix (NASDAQ NURO) News Headlines

Source:

Date	Headline
	Head to Head Analysis: Neurometrix (NURO) versus Irhythm Technologies (IRTC) www.americanbankingnews.com - April 21 at 9:50 AM
	NeuroMetrix, Inc. to Host Earnings Call finance.yahoo.com - April 19 at 8:42 AM
	NeuroMetrix Reports Q1 2018 Financial Results finance.yahoo.com - April 19 at 8:42 AM
	NeuroMetrix to Present Data on Quell Sleep Monitoring Technology at Upcoming American Academy of Neurology Annual Meeting finance.yahoo.com - April 18 at 5:22 PM
	Neurometrix (NURO) Downgraded by ValuEngine www.americanbankingnews.com - April 18 at 1:24 PM
	Neurometrix (NURO) Cut to "Hold" at Zacks Investment Research www.americanbankingnews.com - April 17 at 9:15 PM
	Neurometrix (NURO) Scheduled to Post Quarterly Earnings on Thursday www.americanbankingnews.com - April 15 at 8:15 PM
	Financial Contrast: Neurometrix (NURO) & Restoration Robotics (HAIR) www.americanbankingnews.com - April 13 at 11:35 PM
	NeuroMetrix, Inc. Announces Date for 2018 First Quarter Financial Results Conference Call feeds.benzinga.com - April 11 at 11:16 AM
	NeuroMetrix (NURO) Reports Results of Large Clinical Study of Quell Wearable Pain Relief www.streetinsider.com - April 10 at 5:09 PM
	NeuroMetrix Reports Results of Large Clinical Study of Quell Wearable Pain Relief finance.yahoo.com - April 10 at 5:09 PM
	Neurometrix Inc (NURO) Given Average Recommendation of "Hold" by Analysts www.americanbankingnews.com - April 4 at 11:12 PM
	Neurometrix (NURO) Upgraded at Zacks Investment Research www.americanbankingnews.com - March 26 at 1:58 PM
	Free Research Reports on These Medical Supplies Stocks -- Hill-Rom, NeuroMetrix, Akers Biosciences, and Antares Pharma www.bizjournals.com - March 21 at 9:36 AM
	Should You Buy NeuroMetrix Inc (NASDAQ:NURO) Now? finance.yahoo.com - March 8 at 6:10 PM
	NeuroMetrix to Present Quell Data at 2018 American Pain Society Meeting finance.yahoo.com - March 1 at 5:30 PM
	Contrasting SurModics (SRDX) and Neurometrix (NURO) www.americanbankingnews.com - February 26 at 1:34 AM
	Comparing Neurometrix (NURO) & Palomar Medical Technologies (PMTI) www.americanbankingnews.com - February 12 at 5:12 PM
	NeuroMetrix Inc (NURO) Files 10-K for the Fiscal Year Ended on December 31, 2017 finance.yahoo.com - February 8 at 3:57 PM
	Neurometrix (NURO) Lifted to Sell at ValuEngine www.americanbankingnews.com - February 4 at 7:40 PM
	BRIEF-Neurometrix Inc Says Net Loss Was About $2.9 Mln In Q4 2017 Compared To $2.8 Mln In Q4 2016 www.reuters.com - January 25 at 3:59 PM
	NeuroMetrix Q4 Reports Wider Net Loss, Despite Revenue Growth www.nasdaq.com - January 25 at 3:59 PM
	NeuroMetrix Reports Q4 and Full Year 2017 Financial Results finance.yahoo.com - January 25 at 9:39 AM
	Zacks Investment Research Downgrades Neurometrix (NURO) to Sell www.americanbankingnews.com - January 24 at 9:42 AM
	Symmetry Medical (SMA) versus Neurometrix (NURO) Financial Review www.americanbankingnews.com - January 23 at 9:28 PM
	Intersect ENT (XENT) vs. Neurometrix (NURO) Head to Head Analysis www.americanbankingnews.com - January 23 at 1:18 AM
	NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2017 Financial Results Conference Call finance.yahoo.com - January 18 at 4:12 PM
	Here’s Why Neurometrix Inc Rose as Much as 60% Today finance.yahoo.com - January 17 at 4:43 PM
	NeuroMetrix Reports Preliminary 2017 Financial Highlights finance.yahoo.com - January 8 at 10:23 AM
	NeuroMetrix to Present at Upcoming Biotech Showcase and Digital Medicine Showcase Conferences feeds.benzinga.com - January 3 at 12:26 PM
	ValuEngine Upgrades Neurometrix (NURO) to Sell www.americanbankingnews.com - December 29 at 10:10 PM
	Head-To-Head Review: NeuroMetrix (NURO) & Orthofix International (OFIX) www.americanbankingnews.com - December 13 at 9:38 PM
	Globus Medical (GMED) & NeuroMetrix (NURO) Financial Survey www.americanbankingnews.com - December 13 at 1:34 PM
	NeuroMetrix (NURO) Announces New U.S. Patent for Quell Wearable Technology www.streetinsider.com - November 30 at 10:52 AM
	NeuroMetrix Announces Issuance of New U.S. Patent for Quell Wearable Technology finance.yahoo.com - November 29 at 10:19 AM
	Contrasting NeuroMetrix (NURO) & Bio-Rad Laboratories (BIO) www.americanbankingnews.com - November 19 at 1:08 AM
	Interested In The Healthcare Industry? Take A Look At NeuroMetrix Inc (NURO) finance.yahoo.com - November 18 at 9:04 AM
	Comparing NeuroMetrix (NURO) and LDR Holding Corp (LDRH) www.americanbankingnews.com - November 15 at 11:24 PM
	What Is NeuroMetrix Inc’s (NURO) Share Price Doing? finance.yahoo.com - November 2 at 7:06 AM
	NeuroMetrix Closes $3.5 Million Equity Offering finance.yahoo.com - November 1 at 7:05 AM
	-$1.60 EPS Expected for NeuroMetrix, Inc. (NURO) This Quarter www.americanbankingnews.com - October 27 at 5:30 AM
	NeuroMetrix (NURO) vs. Integra LifeSciences Holdings Corporation (IART) Head-To-Head Survey www.americanbankingnews.com - October 26 at 7:58 AM
	NeuroMetrix, Inc. :NURO-US: Earnings Analysis: Q3, 2017 By the Numbers : October 24, 2017 finance.yahoo.com - October 25 at 8:24 AM
	Comparing K2M Group Holdings (KTWO) & NeuroMetrix (NURO) www.americanbankingnews.com - October 22 at 6:22 AM
	NeuroMetrix, Inc. (NURO) Given Buy Rating at HC Wainwright www.americanbankingnews.com - October 21 at 2:22 PM
	NeuroMetrix Reports Q3 2017 Financial Results finance.yahoo.com - October 20 at 6:58 AM
	Edited Transcript of NURO earnings conference call or presentation 19-Oct-17 12:00pm GMT finance.yahoo.com - October 20 at 6:58 AM
	Head to Head Review: NeuroMetrix (NURO) vs. Landauer (LDR) www.americanbankingnews.com - October 12 at 4:32 AM
	NeuroMetrix, Inc. Announces Date for 2017 Third Quarter Financial Results Conference Call finance.yahoo.com - October 11 at 5:06 AM
	NeuroMetrix, Inc. (NURO) Set to Announce Earnings on Wednesday www.americanbankingnews.com - October 11 at 1:56 AM

Neurometrix (NASDAQ:NURO) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Neurometrix (NASDAQ:NURO) Income Statement, Balance Sheet and Cash Flow Statement

Neurometrix (NASDAQ NURO) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff